Navigation Links
Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Date:5/14/2009

SEATTLE, May 14 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that Chief Executive Officer, Mitchell H. Gold, M.D., is a finalist for the Ernst & Young Entrepreneur Of The Year(R) 2009 Award in the Pacific Northwest. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mitchell Gold was selected as a finalist from nearly 65 nominations by a panel of independent judges. Award recipients will be announced at a special gala event on June 26, 2009 at the Seattle Sheraton.

"Dendreon is committed to improving the lives of cancer patients through the development of therapies that could someday offer safer and more effective treatment options to cancer patients in need, so I am thankful for this nomination. On behalf of all of our dedicated employees, we are honored to be recognized for these efforts to transform the way that cancer is treated," stated Dr. Gold.

The Ernst & Young Entrepreneur Of The Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

Regional award recipients are eligible for consideration for the Ernst & Young LLP Entrepreneur Of The Year national program. Award recipients in several national categories, as well as the overall national Ernst & Young Entrepreneur Of The Year award recipient, will be announced at the annual awards gala in Palm Springs, California on November 14, 2009. The awards are the culminating event of the Ernst & Young Strategic Growth Forum, the nation's most prestigious gathering of high-growth, market-leading companies.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepren
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... China Botanic Pharmaceutical Inc. (NYSE AMEX: ... developer, manufacturer and distributor of botanical products, bio-pharmaceuticals ... announced that the Company successfully showcased its all-natural ... recently held in Chengdu, China. ...
... PISGAH FOREST, N.C., May 17, 2011 Responding ... acetaminophen in prescription painkiller combination products, Pisgah Laboratories, ... on abuse deterrent features for opioid drug products. ... ( http://www.uspto.gov ), this new patent application is ...
... Masimo (NASDAQ: ... study published in the American Journal of Surgery ... correlates strongly with invasive laboratory hemoglobin testing and "can ... setting and may potentially decrease the invasiveness of both ...
Cached Biology Technology:China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 2China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 3Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market 2Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market 3New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 2New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 3New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 4New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 6
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
(Date:4/17/2014)... German . If ... of him, he can expect his premises to be trashed. ... the consequences is enough to make restaurant owners pay up. ... their eggs in other birds, nests. If the host birds ... revenge by destroying the entire nest. Consequently, it is beneficial ...
(Date:4/17/2014)... Researchers in France have hit on a novel ... receive the correct and most effective treatment possible., ... the western and developing world. If left untreated, ... to renal failure and other complications. In many ... problem. Clearly a more effective pathological approach to ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... National Laboratory honored more than 165 staff for their ... annual Intellectual Property Commercialization Recognition & Rewards Program banquet. ... materials scientist Jun Liu Inventor of the Year for ... amounts of energy, ease impacts to the electrical grid, ...
... at Emory University, along with partners at the Georgia ... over four years to establish the HERCULES Center at ... Exposures). The grant is the first exposome-based center grant ... Center is funded by the National Institute of Environmental ...
... wrapping of genomic DNA around nucleosomes in the cell ... of Ludwig-Maximilians-Universitaet (LMU) in Munich now describes a mechanism ... nucleosomes for transcription. In higher organisms the genomic ... disk-shaped particles called nucleosomes, each consisting of two pairs ...
Cached Biology News:PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Biochemistry: Unspooling DNA from nucleosomal disks 2
...
... All MagCellect Ferrofluid products ... conjunction with R&D Systems MagCellect ... capacities, this neodymium iron boron ... 12 x 75 mm test ...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: